$331.44
1.59% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US58506Q1094
Symbol
MEDP

Medpace Stock price

$331.44
-51.92 13.54% 1M
-71.83 17.81% 6M
+24.91 8.13% YTD
+83.44 33.65% 1Y
+140.41 73.50% 3Y
+248.31 298.70% 5Y
+303.65 1,092.66% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+5.18 1.59%
ISIN
US58506Q1094
Symbol
MEDP
Sector
Industry

Key metrics

Market capitalization $10.11b
Enterprise Value $9.76b
P/E (TTM) P/E ratio 30.67
EV/FCF (TTM) EV/FCF 19.41
EV/Sales (TTM) EV/Sales 4.81
P/S ratio (TTM) P/S ratio 4.98
P/B ratio (TTM) P/B ratio 13.22
Revenue growth (TTM) Revenue growth 21.36%
Revenue (TTM) Revenue $2.03b
EBIT (operating result TTM) EBIT $381.45m
Free Cash Flow (TTM) Free Cash Flow $502.80m
Cash position $510.89m
EPS (TTM) EPS $10.64
P/E forward 28.06
P/S forward 4.74
EV/Sales forward 4.57
Short interest 4.19%
Show more

Is Medpace a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Medpace Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Medpace forecast:

7x Buy
58%
4x Hold
33%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Medpace forecast:

Buy
58%
Hold
33%
Sell
8%

Financial data from Medpace

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,030 2,030
21% 21%
100%
- Direct Costs 1,479 1,479
22% 22%
73%
551 551
18% 18%
27%
- Selling and Administrative Expenses 141 141
37% 37%
7%
- Research and Development Expense - -
-
-
410 410
13% 13%
20%
- Depreciation and Amortization 28 28
35% 35%
1%
EBIT (Operating Income) EBIT 381 381
20% 20%
19%
Net Profit 340 340
27% 27%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Medpace directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Medpace Stock News

Neutral
Business Wire
3 days ago
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties...
Neutral
GlobeNewsWire
29 days ago
Hagens Berman Encourages MEDP Investors with Substantial Losses to Contact the Firm Hagens Berman Encourages MEDP Investors with Substantial Losses to Contact the Firm
Neutral
GlobeNewsWire
about one month ago
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Medpace Holdings, Inc. (NASDAQ: MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
More Medpace News

Company Profile

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

Head office United States
CEO August Troendle
Employees 5,900
Founded 1992
Website www.medpace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today